Oncodesign announces the nomination of Arnaud Lafforgue as Chief Financial Officer

April 23, 2018


[Press release] Oncodesign: 2017 annual results

April 11, 2018

  • Operating revenue up 77% to €25.91 million
  • R&D spending doubled to €13.9 million
  • Solid operational execution and rigorous management of acquisitions despite various accounting and tax impacts
  • Cash position net of short-term debt of €9.8 million (excluding GSK payment of €7.9 million received in January 2018)
  • Full results of the radiotracer trial expected at the end of Q2 2018 with the possibility of directly entering Phase III


[Press Release] Oncodesign concludes a long term service-based partnership with ERYTECH in oncology

March 27, 2018

  • Oncodesign has become a key ERYTECH partner for conducting preclinical trials under its oncology research programs
  • The partnership aims to establish the mechanism of action and potential of ERYTECH’s eryaspase and erymethionase in the treatment of various solid tumors


By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.